
Healthcare / Pharmaceuticals · NSE / BSE
Emcure Pharmaceuticals Limited, incorporated in 1981, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas. Ranked 13th in domestic sales and 4th in market share in covered markets for MAT September 2023, Emcure is a leader in the gynaecology and HIV antiviral segments. With domestic sales contributing over 50% of total revenue and growing at a CAGR of 10.80% between September 2019 and September 2023, the company has outpaced the Indian pharmaceutical market. It operates five research facilities in India, employing 552 scientists and filing over 1,800 global regulatory documents, including 201 granted patents. Emcure's 13 manufacturing facilities in India produce a wide range of pharmaceutical and biopharmaceutical products, including chiral molecules, iron molecules, and cytotoxic substances. Supported by over 5,000 field personnel and 5,000 stockists across 37 carry-and-forward agents, the company maintains an extensive marketing and distribution network, ensuring strong engagement with healthcare providers and efficient product availability.
Price Band
₹960 – ₹1008
Issue Size
₹1952 Cr
Lot Size
14 shares
GMP
+29.8%
Est. Listing
₹1308
at current GMP
Subscribed
68.40x
overall
Open
3 Jul 2024
Close
5 Jul 2024
Allotment
8 Jul 2024
Refund
9 Jul 2024
Demat Credit
10 Jul 2024
Listing
10 Jul 2024
Designated Registrar: Link Intime India Private Limited
Allotment Date
8 Jul 2024
Basis finalization
Refunds Initiate
9 Jul 2024
Mandate release
Demat Credit
10 Jul 2024
Shares in demat
Listing Debut
10 Jul 2024
Trading begins
Emcure Pharmaceuticals Limited is bringing an initial public offering (IPO) in the Healthcare / Pharmaceuticals sector with an aggregate issue size of ₹1,952.03 Crores. The shares are offered at a price band of ₹960 to ₹1008 per equity share on NSE and BSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2024-07-05, the basis of allotment is scheduled to be finalized on 2024-07-08. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.